International Journal of
Reproductive Biomedicine
Sat, Apr 20, 2024
[Archive]
Volume 7, Issue 2 (7-2009)
IJRM 2009, 7(2): 65-72 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohammad Gholizad L, Zare S, Nejati V, Eyshi Oskooii A. A comparison of the effects of ABVD and ChlVPP chemotherapeutic protocols for Hodgkin's disease on the spermatozoa fertility indices of male rats. IJRM 2009; 7 (2) :65-72
URL: http://ijrm.ir/article-1-146-en.html
URL: http://ijrm.ir/article-1-146-en.html
1- Department of Biology, Science College, Urmia University, Urmia, Iran , lida579@yahoo.com
2- Department of Biology, Science College, Urmia University, Urmia, Iran
3- Department of Oncology, Emam Khomeyni Hospital, Urmia Medical Sciences University, Urmia, Iran
2- Department of Biology, Science College, Urmia University, Urmia, Iran
3- Department of Oncology, Emam Khomeyni Hospital, Urmia Medical Sciences University, Urmia, Iran
Abstract: (2248 Views)
Background: Fertility protection is important in young patients with Hodgkin's lymphoma.
Objective: The goal of this study was to determine the effects of ABVD and ChlVPP chemotherapeutic protocols for Hodgkin's disease on the spermatozoa fertility indices of male rat.
Materials and Methods: After determining tolerance dose of drugs in pilot study, 24 male rats were divided to four groups: ABVD (doxorubicin, bleomycine, vinblastin, dacarbazine) group, ChlVPP (chlorambucil, vinblastin, procarbazine, prednisolone) group and two control groups one for each treatment group. One half of the lethal dose for fifty percent of population was used for treatment of animals in each protocol. Spermatozoa were used for computer- assisted sperm analysis (CASA) and morphology analyses. Heads of spermatozoa were counted.
Results: Body weight, testis and epididymis weights, spermatozoa number, and live ratio in treated rats were significantly less than their control groups (p<0.05) specifically these parameters in ABVD group was less than ChlVPP group (F= 19.6, p=0.000). Spermatozoa morphology in treated groups were more abnormal than control groups (p<0.05). Evaluation of reproductive system efficacy showed that there was no pregnancy in ABVD group and in ChlVPP group there was only one pregnant female (16.6%).
Conclusion: According to this study results, the ChlVPP had fewer side effects than ABVD in tolerance doses on male rats' reproductive system. More clinical trial studies are suggested on Hodgkin's patients. With equal treatment effectiveness, it will be better to use the most reliable and safe treatment especially in young patients.
Objective: The goal of this study was to determine the effects of ABVD and ChlVPP chemotherapeutic protocols for Hodgkin's disease on the spermatozoa fertility indices of male rat.
Materials and Methods: After determining tolerance dose of drugs in pilot study, 24 male rats were divided to four groups: ABVD (doxorubicin, bleomycine, vinblastin, dacarbazine) group, ChlVPP (chlorambucil, vinblastin, procarbazine, prednisolone) group and two control groups one for each treatment group. One half of the lethal dose for fifty percent of population was used for treatment of animals in each protocol. Spermatozoa were used for computer- assisted sperm analysis (CASA) and morphology analyses. Heads of spermatozoa were counted.
Results: Body weight, testis and epididymis weights, spermatozoa number, and live ratio in treated rats were significantly less than their control groups (p<0.05) specifically these parameters in ABVD group was less than ChlVPP group (F= 19.6, p=0.000). Spermatozoa morphology in treated groups were more abnormal than control groups (p<0.05). Evaluation of reproductive system efficacy showed that there was no pregnancy in ABVD group and in ChlVPP group there was only one pregnant female (16.6%).
Conclusion: According to this study results, the ChlVPP had fewer side effects than ABVD in tolerance doses on male rats' reproductive system. More clinical trial studies are suggested on Hodgkin's patients. With equal treatment effectiveness, it will be better to use the most reliable and safe treatment especially in young patients.
Type of Study: Original Article |
References
1. Armstrong AA, Lennard A, Alexander FE, Angus B, Proctor SJ, Onions DE, et al. Prognostic significance of Epstein-Barr virus association in Hodgkin's disease. Eur J Cancer 1994; 30: 1045-1046. [DOI:10.1016/0959-8049(94)90157-0]
2. Kennedy BJ, Loeb V, Peterson VM, Donegan WL, Natarajan N, Mettlin C. National survey of patterns of care for Hodgkin's disease. Cancer 1985; 56: 2547-2556.
https://doi.org/10.1002/1097-0142(19851201)56:11<2547::AID-CNCR2820561102>3.0.CO;2-X [DOI:10.1002/1097-0142(19851201)56:113.0.CO;2-X]
3. Spitz MR, Sider JG, Johnson CC, Butler JJ, Pollack ES, Newell GR. Ethnic patterns of Hodgkin's disease incidence among children and adolescents in the United States, 1973-82. J Natl Cancer Inst 1986; 76: 235-239.
4. Stein RS, Morgan DS. Wintrobe's clinical hematology: chapter 95 Hodgkin diseases. Eleventh edition. U.S.A: Lippincott Williams and Wilkins 2004.
5. Haskell ChM. Cancer treatment: Lymphoid neoplasm. Forth Edition, WB. U.S.A.: Saunders Company 2001; 81-83.
6. Green DM. Fertility and pregnancy outcome after treatment for cancer in childhood or adolescence. The oncologist 1997; 2: 171-179.
7. Howell SJ, Shalet SM. Testicular function following chemotherapy. Human reproduction update 2001; 7: 363-369. [DOI:10.1093/humupd/7.4.363]
8. Howell SJ, Shalet SM. Spermatogenesis after Cancer Treatment: Damage and Recovery. JNCI Monographs 2005; 34: 12-17. [DOI:10.1093/jncimonographs/lgi003]
9. Sieniawski M, Reineke T, Josting A, Nogova L, Behringer K, Halbsguth T, et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol 2008; 19: 1795-1801. [DOI:10.1093/annonc/mdn376]
10. Viviani S, Ragni G, Santoro A, Perotti L, Caccamo E, Negretti E, et al. Testicular dysfunction in Hodgkin's disease before and after treatment. Eur J Cancer 1991; 27: 1389-1392. [DOI:10.1016/0277-5379(91)90017-8]
11. Brydoy M, Sophie D, Fossa OD, Trine B. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncologica 2007; 46: 480 - 489. [DOI:10.1080/02841860601166958]
12. Anselmo AP, Cartoni C, Bellantuono P, Maurizi-Enrici R, Aboulkair N, Ermini M. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP. Haematologica 1990; 75: 155-158.
13. Fitoussi O, Eghbali H, Tchen N, Berjon JP, Soubeyran P, Hoerni B. Semen analysis and cryoconservation before treatment in Hodgkin's disease. Ann Oncol 2000; 11: 679-684. [DOI:10.1023/A:1008353728560]
14. Weiner Louis M. The cancer protocol guide: Lymphomas. U.S.A.: Fox chase cancer center; 2000; 81-82.
15. Pryor JL, Hughes C, Foster W, Hales BF, Robaire B. Critical windows of exposure for children's health: the reproductive system in animals and humans, Environ Health Perspect Jun 2000; 108: 491-503. [DOI:10.1289/ehp.00108s3491]
16. Bachmann K, Pardoe D, White D. Scaling basic toxicokinetic parameters from rat to man. Environ Health Perspect 1996; 104: 400 -407. [DOI:10.1289/ehp.96104400]
17. Bieber AM, Marcon L, Hales BF, Robaire B. Effects of Chemotherapeutic agents for testicular cancer on the male rat reproductive system, spermatozoa, and fertility. Journal of Andrology 2006; 27: 189-200 [DOI:10.2164/jandrol.05103]
18. Robb GW, Amann RP, Killian GJ. Daily sperm production and epididymal sperm reserves of pubertal and adult rats. J Reprod Fertil 1978; 54: 103 -107. [DOI:10.1530/jrf.0.0540103]
19. Slott VL, Suarez JD, Poss PM, Linder RE, Strader LF, Perreault SD. Optimization of the Hamilton-Thorn Computerized Sperm Motility Analysis System for Use with Rat Spermatozoa in Toxicological Studies. Fundam Appl Toxicol 1993; 21: 298-307. [DOI:10.1006/faat.1993.1102]
20. Klinefelter GR, Gray LE, Suarez JD. The method of sperm collection significantly influences sperm motion parameters following ethane dimethanesulfonate administration in the rat. Reprod Toxicol 1991; 5: 39-44. [DOI:10.1016/0890-6238(91)90108-R]
21. Charak BS, Gupta R, Mandrekar P, Sheth NA, Banavali SD, Saikia TK. Testicular dysfunction after cyclophosphamide -vincristine-procarbazine-prednisolone chemotherapy for advanced Hodgkin's disease. A long-term follow-up study. Cancer 1990; 1, 65: 1903-1906.
https://doi.org/10.1002/1097-0142(19900501)65:9<1903::AID-CNCR2820650905>3.0.CO;2-# [DOI:10.1002/1097-0142(19900501)65:93.0.CO;2-#]
22. Mackie EJ, Radford M, Shalet SM. Gonadal function following chemotherapy for childhood Hodgkin's disease. Med Pediatr Oncol 1996; 27: 74-78.
https://doi.org/10.1002/(SICI)1096-911X(199608)27:2<74::AID-MPO2>3.0.CO;2-Q [DOI:10.1002/(SICI)1096-911X(199608)27:23.0.CO;2-Q]
23. Papadakis V, Vlachopapadopoulou E, Van Syckle K, Ganshaw L, Kalmanti M, Tan C, Sklar C. Gonadal function in young patients successfully treated for Hodgkin's disease. Med Pediatr Oncol 1999; 32: 366-372.
https://doi.org/10.1002/(SICI)1096-911X(199905)32:5<366::AID-MPO10>3.0.CO;2-7 [DOI:10.1002/(SICI)1096-911X(199905)32:53.0.CO;2-7]
24. Shalet SM, Hann IM, Lendon M, Morris Jones PH, Beardwell CG. Testicular function after combination chemotherapy in childhood for acute lymphoblastic leukaemia. Arch. Dis Child 1981; 56: 275-278. [DOI:10.1136/adc.56.4.275]
25. Wallace WH, Shalet SM, Lendon M, Morris-Jones PH. Male fertility in long-term survivors of acute lymphoblastic leukaemia in childhood. Int J Androl 1991; 14: 312-319. [DOI:10.1111/j.1365-2605.1991.tb01098.x]
26. Wallace WH, Shalet SM, Crowne EC, Morris-Jones PH, Gattamaneni HR, Price DA. Gonadal dysfunction due to cis-platinum. Med Pediatr Oncol 1989; 17: 409-413. [DOI:10.1002/mpo.2950170510]
27. Watson AR, Rance CP, Bain J. Long-term effects of cyclophosphamide on testicular function. Br. Med J 1985; 291: 1457-1460. [DOI:10.1136/bmj.291.6507.1457]
28. Heikens J, Behrendt H, Adriaanse R, Berghout A. Irreversible gonadal damage in male survivors of pediatric Hodgkin's disease. Cancer 1996; 78: 2020-2024.
https://doi.org/10.1002/(SICI)1097-0142(19961101)78:9<2020::AID-CNCR25>3.0.CO;2-Y [DOI:10.1002/(SICI)1097-0142(19961101)78:93.0.CO;2-Y]
29. Drasga RE, Einborn LH, Williams SD, Patel DN, Stevens EE. Fertility after chemotherapy for testicular cancer after chemotherapy. Eur J Cancer Clin Oncol 1986; 22: 289-294.
30. Ganesh Kumar S , Narayana K , Bairy KL, D'Souza Urban JA, Paul Samuel Vijaya, Opalakrishna K. Dacarbazine induces genotoxic and cytotoxic germ cell damage with concomitant decrease in testosterone and increase in lactate dehydrogenase concentration in the testis. Mrgentox 2006; 607: 240-252. [DOI:10.1016/j.mrgentox.2006.04.019]
31. Bahadur G, Ozturk O, Muneer A, Wafa R, Ashraf A, Jaman N, et al. Semen quality before and after gonadotoxic treatment. Human reproduction 2005; 20: 774-781. [DOI:10.1093/humrep/deh671]
32. Thomson AB, Campbell AJ, Irvine DC, Anderson RA, Kelnar CJ, Wallace WH. Semen quality and spermatozoal DNA integrity in survivors of childhood cancer: a case-control study. Lancet 2002; 360: 361-367. [DOI:10.1016/S0140-6736(02)09606-X]
33. Kulkarni SS, Sastry PS, Saikia TK, Parikh PM, Gopal R, Advani SH. Gonadal function following ABVD therapy for Hodgkin's disease. Am J Clin Oncol 1997; 20: 354- 357. [DOI:10.1097/00000421-199708000-00006]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
